Prevention of childhood rotavirus disease through the use of Rotarix and RotaTeq vaccines (Q37012078)

17 August 2017

1 reference

title

Prevention of childhood rotavirus disease through the use of Rotarix and RotaTeq vaccines (English)

1 reference

17 August 2017

Philippe Lepage

1

1 reference

17 August 2017

Anne Vergison

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Biological Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

1881-1892

1 reference

Global Illness and Deaths Caused by Rotavirus Disease in Children

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Rotavirus and severe childhood diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Update on rotavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Rotavirus vaccines: current prospects and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Rotavirus infection in Europe: time for effective prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Burden of rotavirus disease in European Union countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Immunity and correlates of protection for rotavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Incidence of group C human rotavirus in central Australia and sequence variation of the VP7 and VP4 genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Human group B rotavirus infections cause severe diarrhea in children and adults in Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Rotavirus types in Europe and their significance for vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Rotavirus infection in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Transmission of rotavirus and other enteric pathogens in the home

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Economics of rotavirus gastroenteritis and vaccination in Europe: what makes sense?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Rotavirus infection in infants as protection against subsequent infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Rotavirus vaccines and vaccination in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Clinical trials of rotavirus vaccines in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Intussusception among infants given an oral rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Intussusception among young children in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

More on RotaShield and intussusception: the role of age at the time of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Urinary myiasis associated with ureteral stent placements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

A short report on highlights of world-wide development of RIX4414: a Latin American experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Prevention of rotavirus disease: guidelines for use of rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Development of candidate rotavirus vaccines derived from neonatal strains in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Characterization of G10P[11] rotaviruses causing acute gastroenteritis in neonates and infants in Vellore, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Evaluation of circulating intestinally committed memory B cells in children vaccinated with attenuated human rotavirus vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Rotavirus vaccines: targeting the developing world

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Reappraisal of the Association of Intussusception with the Licensed Live Rotavirus Vaccine Challenges Initial Conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Cost-effectiveness and potential impact of rotavirus vaccination in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

Rotavirus Vaccines: An Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1881

10.1517/14712598.7.12.1881

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference